




PHARMACEUTICAL 2017

Tonix Pharmaceuticals Holding Corp.
Rank 186 of 292





RealRate

PHARMACEUTICAL 2017

Tonix Pharmaceuticals Holding Corp. Rank 186 of 292

The relative strengths and weaknesses of Tonix Pharmaceuticals Holding Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tonix Pharmaceuticals Holding Corp. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Tonix Pharmaceuticals Holding Corp. is the variable Net Income, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is 32%, being 29% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	27,140
Cost of Goods Sold	0
Intangible Assets	120
Liabilities, Current	2,116
Liabilities, Non-Current	0
Other Assets	100
Other Compr. Net Income	10
Other Expenses	0
Other Liabilities	33
Other Net Income	127
Other Revenues	0
Property and Equipment	150
Research and Development	28,533
Selling, General and Administrative Expense	10,436

Output Variable	Value in 1000 USD
Assets	27,510
Liabilities	2,149
Expenses	38,969
Revenues	0
Stockholders Equity	25,361
Net Income	-38,842
Comprehensive Net Income	-38,837
Economic Capital Ratio	32%